期刊
AMERICAN JOURNAL OF KIDNEY DISEASES
卷 64, 期 2, 页码 290-304出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2013.12.018
关键词
Chronic kidney disease-mineral and bone disorder (CKD-MBD); osteoporosis; renal failure; bone histomorphometry; parathyroid hormone (PTH); bone-specific alkaline phosphatase
资金
- Amgen
- Eli Lilly and Co
- Merck
- Radius Health Inc
- Takeda
Osteoporosis is defined as a condition of impairment in bone strength due to low bone mineral density and poor bone quality and predisposes individuals to an increased risk of fractures. Osteoporosis may coexist with chronic kidney disease-mineral and bone disorder (CKD-MBD) and osteoporotic fractures occur in all stages of CKD. Management of osteoporosis in CKD should consider the pathophysiology of both disorders. Diagnosis and management of osteoporosis in patients with stages 1-3 CKD and patients without CKD are similar, but diagnosis and management decisions differ greatly once patients have stages 4-5 CKD. Discriminating between osteoporosis and CKD-MBD is best accomplished with quantitative bone histomorphometry. Biochemical markers, especially intact parathyroid hormone and bone-specific alkaline phosphatase, also may be helpful. When the diagnosis of osteoporosis is established, management in stages 4-5 CKD may include antiresorptive or anabolic agents, though evidence for efficacy is marginal in advanced CKD. (C) 2014 by the National Kidney Foundation, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据